1
|
Yan LL, Wei XH, Shi QP, Pan CS, Li KY, Zhang B, Wang XG, Zheng B, Wang MX, Yan L, Huang P, Liu J, Fan JY, Li H, Wang CS, Chen M, Han JY. Cardiotonic Pills® protects from myocardial fibrosis caused by in stent restenosis in miniature pigs. PHYTOMEDICINE : INTERNATIONAL JOURNAL OF PHYTOTHERAPY AND PHYTOPHARMACOLOGY 2022; 106:154405. [PMID: 36067659 DOI: 10.1016/j.phymed.2022.154405] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/21/2022] [Revised: 07/18/2022] [Accepted: 08/17/2022] [Indexed: 06/15/2023]
Abstract
BACKGROUND Stent implantation has been increasingly applied for the treatment of obstructive coronary artery disease, which, albeit effective, often harasses patients by in-stent restenosis (ISR). PURPOSE The present study was to explore the role of compound Chinese medicine Cardiotonic Pills® (CP) in attenuating ISR-evoked myocardial injury and fibrosis. STUDY DESIGN Chinese miniature pigs were used to establish ISR model by implanting obsolete degradable stents into coronary arteries. Quantitative coronary angiography (QCA) was performed to confirm the success of the model. METHODS CP was given at 0.2 g/kg daily for 30 days after ISR. On day 30 and 60 after stent implantation, the myocardial infarct and myocardial blood flow (MBF) were assessed. Myocardial histology was evaluated by hematoxylin-eosin and Masson's trichrome staining. The content of ATP, MPO, and the activity of mitochondrial respiratory chain complex Ⅳ were determined by ELISA. Western blot was performed to assess the expression of ATP5D and related signaling proteins, and the mediators of myocardial fibrosis. RESULTS Treatment with CP diminished myocardial infarct size, retained myocardium structure, attenuated myocardial fibrosis, and restored MBF. CP ameliorated energy metabolism disorder, attenuated TGFβ1 up-regulation and reversed its downstream gene expression, such as Smad6 and Smad7, and inhibited the increased expression of MCP-1, PR S19, MMP-2 and MMP-9. CONCLUSION CP effectively protects myocardial structure and function from ISR challenge, possibly by regulating energy metabolism via inactivation of RhoA/ROCK signaling pathway and inhibition of monocyte chemotaxis and TGF β1/Smads signaling pathway.
Collapse
Affiliation(s)
- Lu-Lu Yan
- Tasly Microcirculation Research Center, Peking University Health Science Center, Haidian District, Beijing 100191, China; Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People's Republic of China, Haidian District, Beijing 100191, China; State Key Laboratory of Core Technology in Innovative Chinese Medicine, Haidian District, Beijing 100191, China; Beijing Laboratory of Integrative Microangiopathy, Haidian District, Beijing 100191, China
| | - Xiao-Hong Wei
- Tasly Microcirculation Research Center, Peking University Health Science Center, Haidian District, Beijing 100191, China; Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People's Republic of China, Haidian District, Beijing 100191, China; State Key Laboratory of Core Technology in Innovative Chinese Medicine, Haidian District, Beijing 100191, China; Beijing Laboratory of Integrative Microangiopathy, Haidian District, Beijing 100191, China; Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University, Haidian District, Beijing 100191, China
| | - Qiu-Ping Shi
- Beijing Laboratory of Integrative Microangiopathy, Haidian District, Beijing 100191, China; Department of Cardiology, Peking University First Hospital, XiCheng District, Beijing 100034, China
| | - Chun-Shui Pan
- Tasly Microcirculation Research Center, Peking University Health Science Center, Haidian District, Beijing 100191, China; Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People's Republic of China, Haidian District, Beijing 100191, China; State Key Laboratory of Core Technology in Innovative Chinese Medicine, Haidian District, Beijing 100191, China; Beijing Laboratory of Integrative Microangiopathy, Haidian District, Beijing 100191, China
| | - Kai-Yin Li
- Beijing Laboratory of Integrative Microangiopathy, Haidian District, Beijing 100191, China; Department of Cardiology, Peking University First Hospital, XiCheng District, Beijing 100034, China
| | - Bin Zhang
- Beijing Laboratory of Integrative Microangiopathy, Haidian District, Beijing 100191, China; Department of Cardiology, Peking University First Hospital, XiCheng District, Beijing 100034, China
| | - Xin-Gang Wang
- Beijing Laboratory of Integrative Microangiopathy, Haidian District, Beijing 100191, China; Department of Cardiology, Peking University First Hospital, XiCheng District, Beijing 100034, China
| | - Bo Zheng
- Beijing Laboratory of Integrative Microangiopathy, Haidian District, Beijing 100191, China; Department of Cardiology, Peking University First Hospital, XiCheng District, Beijing 100034, China
| | - Ming-Xia Wang
- Tasly Microcirculation Research Center, Peking University Health Science Center, Haidian District, Beijing 100191, China; Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People's Republic of China, Haidian District, Beijing 100191, China; State Key Laboratory of Core Technology in Innovative Chinese Medicine, Haidian District, Beijing 100191, China; Beijing Laboratory of Integrative Microangiopathy, Haidian District, Beijing 100191, China
| | - Li Yan
- Tasly Microcirculation Research Center, Peking University Health Science Center, Haidian District, Beijing 100191, China; Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People's Republic of China, Haidian District, Beijing 100191, China; State Key Laboratory of Core Technology in Innovative Chinese Medicine, Haidian District, Beijing 100191, China; Beijing Laboratory of Integrative Microangiopathy, Haidian District, Beijing 100191, China
| | - Ping Huang
- Tasly Microcirculation Research Center, Peking University Health Science Center, Haidian District, Beijing 100191, China; Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People's Republic of China, Haidian District, Beijing 100191, China; State Key Laboratory of Core Technology in Innovative Chinese Medicine, Haidian District, Beijing 100191, China; Beijing Laboratory of Integrative Microangiopathy, Haidian District, Beijing 100191, China
| | - Jian Liu
- Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People's Republic of China, Haidian District, Beijing 100191, China; State Key Laboratory of Core Technology in Innovative Chinese Medicine, Haidian District, Beijing 100191, China; Beijing Laboratory of Integrative Microangiopathy, Haidian District, Beijing 100191, China; Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University, Haidian District, Beijing 100191, China
| | - Jing-Yu Fan
- Tasly Microcirculation Research Center, Peking University Health Science Center, Haidian District, Beijing 100191, China; Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People's Republic of China, Haidian District, Beijing 100191, China; State Key Laboratory of Core Technology in Innovative Chinese Medicine, Haidian District, Beijing 100191, China; Beijing Laboratory of Integrative Microangiopathy, Haidian District, Beijing 100191, China; Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University, Haidian District, Beijing 100191, China
| | - Huan Li
- Tasly Microcirculation Research Center, Peking University Health Science Center, Haidian District, Beijing 100191, China; Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People's Republic of China, Haidian District, Beijing 100191, China; State Key Laboratory of Core Technology in Innovative Chinese Medicine, Haidian District, Beijing 100191, China; Beijing Laboratory of Integrative Microangiopathy, Haidian District, Beijing 100191, China
| | - Chuan-She Wang
- Tasly Microcirculation Research Center, Peking University Health Science Center, Haidian District, Beijing 100191, China; Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People's Republic of China, Haidian District, Beijing 100191, China; State Key Laboratory of Core Technology in Innovative Chinese Medicine, Haidian District, Beijing 100191, China; Beijing Laboratory of Integrative Microangiopathy, Haidian District, Beijing 100191, China; Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University, Haidian District, Beijing 100191, China
| | - Ming Chen
- Beijing Laboratory of Integrative Microangiopathy, Haidian District, Beijing 100191, China; Department of Cardiology, Peking University First Hospital, XiCheng District, Beijing 100034, China.
| | - Jing-Yan Han
- Tasly Microcirculation Research Center, Peking University Health Science Center, Haidian District, Beijing 100191, China; Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People's Republic of China, Haidian District, Beijing 100191, China; State Key Laboratory of Core Technology in Innovative Chinese Medicine, Haidian District, Beijing 100191, China; Beijing Laboratory of Integrative Microangiopathy, Haidian District, Beijing 100191, China; Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University, Haidian District, Beijing 100191, China.
| |
Collapse
|
2
|
Hu Y, Sun J, Wang T, Wang H, Zhao C, Wang W, Yan K, Yan X, Sun H. Compound Danshen Dripping Pill inhibits high altitude-induced hypoxic damage by suppressing oxidative stress and inflammatory responses. PHARMACEUTICAL BIOLOGY 2021; 59:1585-1593. [PMID: 34808069 PMCID: PMC8635678 DOI: 10.1080/13880209.2021.1998139] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 04/02/2021] [Revised: 10/12/2021] [Accepted: 10/21/2021] [Indexed: 06/13/2023]
Abstract
CONTEXT Previous studies indicate that compound Danshen Dripping Pill (CDDP) improves the adaptation to high-altitude exposure. However, its mechanism of action is not clear. OBJECTIVE To explore the protective effect of CDDP on hypobaric hypoxia (HH) and its possible mechanism. MATERIALS AND METHODS A meta-analysis of 1051 human volunteers was performed to evaluate the effectiveness of CDDP at high altitudes. Male Sprague-Dawley rats were randomized into 5 groups (n = 6): control at normal pressure, model, CDDP-170 mg/kg, CDDP-340 mg/kg and acetazolamide groups. HH was simulated at an altitude of 5500 m for 24 h. Animal blood was collected for arterial blood-gas analysis and cytokines detection and their organs were harvested for pathological examination. Expression levels of AQP1, NF-κB and Nrf2 were determined by immunohistochemical staining. RESULTS The meta-analysis data indicated that the ratio between the combined RR of the total effective rate and the 95% CI was 0.23 (0.06, 0.91), the SMD and 95% CI of SO2 was 0.37 (0.12, 0.62). Pre-treatment of CDDP protected rats from HH-induced pulmonary edoema and heart injury, left-shifted oxygen-dissociation curve and decreased P50 (30.25 ± 3.72 vs. 37.23 ± 4.30). Mechanistically, CDDP alleviated HH-reinforced ROS by improving SOD and GPX1 while inhibiting pro-inflammatory cytokines and NF-κB expression. CDDP also decreased HH-evoked D-dimer, erythrocyte aggregation and blood hemorheology, promoting AQP1 and Nrf2 expression. DISCUSSION AND CONCLUSIONS Pre-treatment with CDDP could prevent HH-induced tissue damage, oxidative stress and inflammatory response. Suppressed NF-κB and up-regulated Nrf2 might play significant roles in the mechanism of CDDP.
Collapse
Affiliation(s)
- Yunhui Hu
- GeneNet Pharmaceuticals Co. Ltd, Tianjin, P.R. China
| | - Jia Sun
- GeneNet Pharmaceuticals Co. Ltd, Tianjin, P.R. China
| | - Tongxing Wang
- GeneNet Pharmaceuticals Co. Ltd, Tianjin, P.R. China
| | - Hairong Wang
- GeneNet Pharmaceuticals Co. Ltd, Tianjin, P.R. China
| | - Chunlai Zhao
- GeneNet Pharmaceuticals Co. Ltd, Tianjin, P.R. China
| | - Wenjia Wang
- GeneNet Pharmaceuticals Co. Ltd, Tianjin, P.R. China
| | - Kaijing Yan
- GeneNet Pharmaceuticals Co. Ltd, Tianjin, P.R. China
- The State Key Laboratory of Core Technology in Innovative Chinese Medicine, Tasly Academy, Tasly Holding Group Co., Ltd, Tianjin, China
- Tasly Pharmaceutical Group Co., Ltd, Tianjin, China
| | - Xijun Yan
- GeneNet Pharmaceuticals Co. Ltd, Tianjin, P.R. China
- The State Key Laboratory of Core Technology in Innovative Chinese Medicine, Tasly Academy, Tasly Holding Group Co., Ltd, Tianjin, China
- Tasly Pharmaceutical Group Co., Ltd, Tianjin, China
| | - He Sun
- GeneNet Pharmaceuticals Co. Ltd, Tianjin, P.R. China
- The State Key Laboratory of Core Technology in Innovative Chinese Medicine, Tasly Academy, Tasly Holding Group Co., Ltd, Tianjin, China
- Tasly Pharmaceutical Group Co., Ltd, Tianjin, China
| |
Collapse
|
3
|
Zhang J, Hu K, Di L, Wang P, Liu Z, Zhang J, Yue P, Song W, Zhang J, Chen T, Wang Z, Zhang Y, Wang X, Zhan C, Cheng YC, Li X, Li Q, Fan JY, Shen Y, Han JY, Qiao H. Traditional herbal medicine and nanomedicine: Converging disciplines to improve therapeutic efficacy and human health. Adv Drug Deliv Rev 2021; 178:113964. [PMID: 34499982 DOI: 10.1016/j.addr.2021.113964] [Citation(s) in RCA: 54] [Impact Index Per Article: 18.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2021] [Revised: 08/28/2021] [Accepted: 09/01/2021] [Indexed: 02/08/2023]
Abstract
Traditional herbal medicine (THM), an ancient science, is a gift from nature. For thousands of years, it has helped humans fight diseases and protect life, health, and reproduction. Nanomedicine, a newer discipline has evolved from exploitation of the unique nanoscale morphology and is widely used in diagnosis, imaging, drug delivery, and other biomedical fields. Although THM and nanomedicine differ greatly in time span and discipline dimensions, they are closely related and are even evolving toward integration and convergence. This review begins with the history and latest research progress of THM and nanomedicine, expounding their respective developmental trajectory. It then discusses the overlapping connectivity and relevance of the two fields, including nanoaggregates generated in herbal medicine decoctions, the application of nanotechnology in the delivery and treatment of natural active ingredients, and the influence of physiological regulatory capability of THM on the in vivo fate of nanoparticles. Finally, future development trends, challenges, and research directions are discussed.
Collapse
|
4
|
Wei XH, Guo X, Pan CS, Li H, Cui YC, Yan L, Fan JY, Deng JN, Hu BH, Chang X, He SY, Yan LL, Sun K, Wang CS, Han JY. Quantitative Proteomics Reveal That Metabolic Improvement Contributes to the Cardioprotective Effect of T 89 on Isoproterenol-Induced Cardiac Injury. Front Physiol 2021; 12:653349. [PMID: 34262469 PMCID: PMC8273540 DOI: 10.3389/fphys.2021.653349] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2021] [Accepted: 04/12/2021] [Indexed: 02/03/2023] Open
Abstract
Background T89, a traditional Chinese medicine, has passed phase II, and is undergoing phase III clinical trials for treatment of ischemic cardiovascular disease by the US FDA. However, the role of T89 on isoproterenol (ISO)-induced cardiac injury is unknown. The present study aimed to explore the effect and underlying mechanism of T89 on ISO-induced cardiac injury. Methods Male Sprague-Dawley rats received subcutaneous injection of ISO saline solution at 24 h intervals for the first 3 days and then at 48 h intervals for the next 12 days. T89 at dose of 111.6 and 167.4 mg/kg was administrated by gavage for 15 consecutive days. Rat survival rate, cardiac function evaluation, morphological observation, quantitative proteomics, and Western blotting analysis were performed. Results T89 obviously improved ISO-induced low survival rate, attenuated ISO-evoked cardiac injury, as evidenced by myocardial blood flow, heart function, and morphology. Quantitative proteomics revealed that the cardioprotective effect of T89 relied on the regulation of metabolic pathways, including glycolipid metabolism and energy metabolism. T89 inhibited the enhancement of glycolysis, promoted fatty acid oxidation, and restored mitochondrial oxidative phosphorylation by regulating Eno1, Mcee, Bdh1, Ces1c, Apoc2, Decr1, Acaa2, Cbr4, ND2, Cox 6a, Cox17, ATP5g, and ATP5j, thus alleviated oxidative stress and energy metabolism disorder and ameliorated cardiac injury after ISO. The present study also verified that T89 significantly restrained ISO-induced increase of HSP70/HSP40 and suppressed the phosphorylation of ERK, further restored the expression of CX43, confirming the protective role of T89 in cardiac hypertrophy. Proteomics data are available via ProteomeXchange with identifier PXD024641. Conclusion T89 reduced mortality and improves outcome in the model of ISO-induced cardiac injury and the cardioprotective role of T89 is correlated with the regulation of glycolipid metabolism, recovery of mitochondrial function, and improvement of myocardial energy.
Collapse
Affiliation(s)
- Xiao-Hong Wei
- Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University, Beijing, China.,Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China.,Academy of Integration of Chinese and Western Medicine, Peking University Health Science Center, Beijing, China.,Key Laboratory of Microcirculation, State Administration of Traditional Chinese Medicine, Beijing, China.,Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine, Beijing, China.,State Key Laboratory of Core Technology in Innovative Chinese Medicine, Tianjin, China
| | - Xiao Guo
- Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University, Beijing, China.,Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China.,Academy of Integration of Chinese and Western Medicine, Peking University Health Science Center, Beijing, China.,Key Laboratory of Microcirculation, State Administration of Traditional Chinese Medicine, Beijing, China.,Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine, Beijing, China.,State Key Laboratory of Core Technology in Innovative Chinese Medicine, Tianjin, China
| | - Chun-Shui Pan
- Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China.,Academy of Integration of Chinese and Western Medicine, Peking University Health Science Center, Beijing, China.,Key Laboratory of Microcirculation, State Administration of Traditional Chinese Medicine, Beijing, China.,Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine, Beijing, China.,State Key Laboratory of Core Technology in Innovative Chinese Medicine, Tianjin, China
| | - Huan Li
- Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University, Beijing, China.,Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China.,Academy of Integration of Chinese and Western Medicine, Peking University Health Science Center, Beijing, China.,Key Laboratory of Microcirculation, State Administration of Traditional Chinese Medicine, Beijing, China.,Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine, Beijing, China.,State Key Laboratory of Core Technology in Innovative Chinese Medicine, Tianjin, China
| | - Yuan-Chen Cui
- Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China.,Academy of Integration of Chinese and Western Medicine, Peking University Health Science Center, Beijing, China.,Key Laboratory of Microcirculation, State Administration of Traditional Chinese Medicine, Beijing, China.,Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine, Beijing, China.,State Key Laboratory of Core Technology in Innovative Chinese Medicine, Tianjin, China
| | - Li Yan
- Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China.,Academy of Integration of Chinese and Western Medicine, Peking University Health Science Center, Beijing, China.,Key Laboratory of Microcirculation, State Administration of Traditional Chinese Medicine, Beijing, China.,Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine, Beijing, China.,State Key Laboratory of Core Technology in Innovative Chinese Medicine, Tianjin, China
| | - Jing-Yu Fan
- Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China.,Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine, Beijing, China.,State Key Laboratory of Core Technology in Innovative Chinese Medicine, Tianjin, China
| | - Jing-Na Deng
- Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China.,Academy of Integration of Chinese and Western Medicine, Peking University Health Science Center, Beijing, China.,Key Laboratory of Microcirculation, State Administration of Traditional Chinese Medicine, Beijing, China.,Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine, Beijing, China.,State Key Laboratory of Core Technology in Innovative Chinese Medicine, Tianjin, China
| | - Bai-He Hu
- Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China.,Academy of Integration of Chinese and Western Medicine, Peking University Health Science Center, Beijing, China.,Key Laboratory of Microcirculation, State Administration of Traditional Chinese Medicine, Beijing, China.,Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine, Beijing, China.,State Key Laboratory of Core Technology in Innovative Chinese Medicine, Tianjin, China
| | - Xin Chang
- Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China.,Academy of Integration of Chinese and Western Medicine, Peking University Health Science Center, Beijing, China.,Key Laboratory of Microcirculation, State Administration of Traditional Chinese Medicine, Beijing, China.,Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine, Beijing, China.,State Key Laboratory of Core Technology in Innovative Chinese Medicine, Tianjin, China
| | - Shu-Ya He
- Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University, Beijing, China.,Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China.,Academy of Integration of Chinese and Western Medicine, Peking University Health Science Center, Beijing, China.,Key Laboratory of Microcirculation, State Administration of Traditional Chinese Medicine, Beijing, China.,Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine, Beijing, China.,State Key Laboratory of Core Technology in Innovative Chinese Medicine, Tianjin, China
| | - Lu-Lu Yan
- Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China.,Academy of Integration of Chinese and Western Medicine, Peking University Health Science Center, Beijing, China.,Key Laboratory of Microcirculation, State Administration of Traditional Chinese Medicine, Beijing, China.,Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine, Beijing, China.,State Key Laboratory of Core Technology in Innovative Chinese Medicine, Tianjin, China
| | - Kai Sun
- Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China.,Academy of Integration of Chinese and Western Medicine, Peking University Health Science Center, Beijing, China.,Key Laboratory of Microcirculation, State Administration of Traditional Chinese Medicine, Beijing, China.,Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine, Beijing, China.,State Key Laboratory of Core Technology in Innovative Chinese Medicine, Tianjin, China
| | - Chuan-She Wang
- Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University, Beijing, China.,Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China.,Academy of Integration of Chinese and Western Medicine, Peking University Health Science Center, Beijing, China.,Key Laboratory of Microcirculation, State Administration of Traditional Chinese Medicine, Beijing, China.,Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine, Beijing, China.,State Key Laboratory of Core Technology in Innovative Chinese Medicine, Tianjin, China
| | - Jing-Yan Han
- Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University, Beijing, China.,Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China.,Academy of Integration of Chinese and Western Medicine, Peking University Health Science Center, Beijing, China.,Key Laboratory of Microcirculation, State Administration of Traditional Chinese Medicine, Beijing, China.,Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine, Beijing, China.,State Key Laboratory of Core Technology in Innovative Chinese Medicine, Tianjin, China
| |
Collapse
|
5
|
Meng L, Li Y, Xue C, Ding C, Wang X, Fu R, Li Y, Li X, Dong Z. Compound danshen dripping pills affect the pharmacokinetics of azisartan by regulating the expression of cytochrome P450 2B1, 2C6, and 2C11 in rats. J Pharm Biomed Anal 2021; 195:113887. [PMID: 33418444 DOI: 10.1016/j.jpba.2020.113887] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2020] [Revised: 12/12/2020] [Accepted: 12/29/2020] [Indexed: 12/28/2022]
Abstract
Combination therapies of compound danshen dripping pill (CDDP) and Azilsartan (AZ) represent a promising treatment option in clinical practice in China, but there are no reports on drug-drug interactions between CDDP and AZ. This study investigated the effects of CDDP on the pharmacokinetics of AZ and clarified its potential mechanism. The pharmacokinetic profiles of oral administration of AZ (2 mg/kg) in Sprague-Dawley rats, with or without pre-treatment of CDDP (81, 405, 810 mg/kg/d for 7 d) were investigated using UPLC-MS/MS. The main pharmacokinetic parameters were calculated and compared. The MS analysis was performed in positive ionization mode. The purpose of chromatographic separation of AZ and the internal standard (IS, Valsartan) was finished on a Waters XBridge BEH C18 column (2.1 × 100 mm, 2.5 μm). The mobile phase was acetonitrile and 0.1 % formic acid-water with gradient elution at a flow rate of 0.4 mL/min. The mRNA and protein levels of CYP2B1, CYP2C6, and CYP2C11 in the rat liver were detected by qRT-PCR and western blot, respectively. The results indicated that low, medium and high doses of CDDP significantly increased the Cmax (6.47 ± 2.28, 6.51 ± 1.99, 7.04 ± 1.31 vs. 3.30 ± 1.87) of AZ, compared with that in the AZ single-drug group (p<0.05). The AUC0-t of AZ (47.77 ± 23.41, 50.69 ± 25.46, 54.50 ± 11.57 vs. 26.85 ± 16.79) tended to increase in combination with CDDP. The gene and protein expression levels of CYP2B1, CYP2C6, and CYP2C11 were significantly reduced in the rat liver by CDDP. CDDP may diminish the AZ metabolism in vivo by suppressing the expression of the CYP2B1, CYP2C6, and CYP2C11 enzymes. This observation suggested the occurrence of potential interactions between CDDP and AZ when clinically administered as combination therapy, which may require adjustment of the clinical dose of AZ.
Collapse
Affiliation(s)
- Lu Meng
- Graduate School, Hebei Medical University, Shijiazhuang, Hebei, 050017, China; Department of Pharmacy, Hebei General Hospital, Shijiazhuang, Hebei, 050051, China
| | - Ying Li
- Department of Pharmacy, Hebei General Hospital, Shijiazhuang, Hebei, 050051, China
| | - Chaojun Xue
- Department of Pharmacy, Hebei General Hospital, Shijiazhuang, Hebei, 050051, China
| | - Congyang Ding
- Graduate School, Hebei Medical University, Shijiazhuang, Hebei, 050017, China; Department of Pharmacy, Hebei General Hospital, Shijiazhuang, Hebei, 050051, China
| | - Xiaonan Wang
- Graduate School, Hebei Medical University, Shijiazhuang, Hebei, 050017, China; Department of Pharmacy, Hebei General Hospital, Shijiazhuang, Hebei, 050051, China
| | - Ran Fu
- Graduate School, Hebei Medical University, Shijiazhuang, Hebei, 050017, China; Department of Pharmacy, Hebei General Hospital, Shijiazhuang, Hebei, 050051, China
| | - Yajing Li
- Department of Pharmacy, Hebei General Hospital, Shijiazhuang, Hebei, 050051, China
| | - Xiao Li
- Department of Pharmacy, Hebei General Hospital, Shijiazhuang, Hebei, 050051, China
| | - Zhanjun Dong
- Department of Pharmacy, Hebei General Hospital, Shijiazhuang, Hebei, 050051, China.
| |
Collapse
|
6
|
Total Salvianolic Acid Injection Prevents Ischemia/Reperfusion-Induced Myocardial Injury Via Antioxidant Mechanism Involving Mitochondrial Respiratory Chain Through the Upregulation of Sirtuin1 and Sirtuin3. Shock 2020; 51:745-756. [PMID: 29863652 PMCID: PMC6511432 DOI: 10.1097/shk.0000000000001185] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Supplemental Digital Content is available in the text Sirtuin1 (Sirt1) and Sirtuin3 (Sirt3) are known to participate in regulating mitochondrial function. However, whether Total Salvianolic Acid Injection (TSI) protects against myocardial ischemia/reperfusion (I/R) injury through regulating Sirt1, Sirt3, and mitochondrial respiratory chain complexes is unclear. The aim of this study was to explore the effects of TSI on I/R-induced myocardial injury and the underlying mechanism. Male Sprague–Dawley rats were subjected to 30 min occlusion of the left anterior descending coronary artery followed by 90 min reperfusion with or without TSI treatment (8 mg/kg/h). The results demonstrated that TSI attenuated I/R-induced myocardial injury by the reduced infarct size, recovery of myocardial blood flow, and decreased cardiac apoptosis. Moreover, TSI protected heart from oxidative insults, such as elevation of myeloperoxidase, malondialdehyde, hydrogen peroxide, ROS, as well as attenuated I/R-elicited downregulation of Sirt1, Sirt3, NADH dehydrogenase [ubiquinone] 1 alpha subcomplex 10 (NDUFA10), succinate dehydrogenase complex, subunit A, flavoprotein variant (SDHA), and restoring mitochondrial respiratory chain complexes activity. The in vitro study in H9c2 cells using siRNA transfection further confirmed the critical role of Sirt1 and Sirt3 in the effect of TSI on the expression of NDUFA10 and SDHA. These results demonstrated that TSI attenuated I/R-induced myocardial injury via inhibition of oxidative stress, which was related to the activation of NDUFA10 and SDHA through the upregulation of Sirt1 and Sirt3.
Collapse
|
7
|
Downregulated PEG3 ameliorates cardiac fibrosis and myocardial injury in mice with ischemia/reperfusion through the NF-κB signaling pathway. J Bioenerg Biomembr 2020; 52:143-154. [PMID: 32350757 DOI: 10.1007/s10863-020-09831-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2019] [Accepted: 03/31/2020] [Indexed: 10/24/2022]
Abstract
Expression of paternally-expressed gene 3 (PEG3) has been identified in new cardiac adult stem cell population, which is involved in post-myocardial infarction remodeling. The cardiac fibroblasts function in the repair and remodeling events after myocardial ischemia, while the role of PEG3 in these events has not been investigated yet. In this study, artificial knockdown of PEG3 through p-LV-GFP-sh-PEG3 injection was performed in a ischemia/reperfusion (I/R) mouse model to explore the role of PEG3 in cardiac fibrosis, myocardial injury and cardiomyocyte apoptosis. Besides, the involvement of nuclear factor kappa B (NF-κB) pathway was illuminated by transduction of inhibitor pyrrolidine dithiocarbamate (PDTC). Both shRNA-mediated silencing of PEG3 and inhibition of the NF-κB signaling pathway were shown to significantly reduce myocardial injury, infarction size, alleviated myocardium remodeling and cardiac fibrosis, along with repressed cardiomyocyte apoptosis. Additionally, we also found that the NF-κB signaling pathway activation was blocked by PEG3 silencing, which could further enhance the protective effects of PEG3 inhibition against I/R induced injury. This study highlights the importance of PEG3 silencing in preventing cardiac fibrosis and myocardial injury after I/R by inactivating the NF-κB signaling pathway.
Collapse
|
8
|
Mourouzis K, Oikonomou E, Siasos G, Tsalamadris S, Vogiatzi G, Antonopoulos A, Fountoulakis P, Goliopoulou A, Papaioannou S, Tousoulis D. Pro-inflammatory Cytokines in Acute Coronary Syndromes. Curr Pharm Des 2020; 26:4624-4647. [PMID: 32282296 DOI: 10.2174/1381612826666200413082353] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2019] [Accepted: 04/01/2020] [Indexed: 12/12/2022]
Abstract
BACKGROUND Over the last decades, the role of inflammation and immune system activation in the initiation and progression of coronary artery disease (CAD) has been established. OBJECTIVES The study aimed to present the interplay between cytokines and their actions preceding and shortly after ACS. METHODS We searched in a systemic manner the most relevant articles to the topic of inflammation, cytokines, vulnerable plaque and myocardial infarction in MEDLINE, COCHRANE and EMBASE databases. RESULTS Different classes of cytokines (intereleukin [IL]-1 family, Tumor necrosis factor-alpha (TNF-α) family, chemokines, adipokines, interferons) are implicated in the entire process leading to destabilization of the atherosclerotic plaque, and consequently, to the incidence of myocardial infarction. Especially IL-1 and TNF-α family are involved in inflammatory cell accumulation, vulnerable plaque formation, platelet aggregation, cardiomyocyte apoptosis and adverse remodeling following the myocardial infarction. Several cytokines such as IL-6, adiponectin, interferon-γ, appear with significant prognostic value in ACS patients. Thus, research interest focuses on the modulation of inflammation in ACS to improve clinical outcomes. CONCLUSION Understanding the unique characteristics that accompany each cytokine-cytokine receptor interaction could illuminate the signaling pathways involved in plaque destabilization and indicate future treatment strategies to improve cardiovascular prognosis in ACS patients.
Collapse
Affiliation(s)
- Konstantinos Mourouzis
- 1st Department of Cardiology, 'Hippokration' Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece
| | - Evangelos Oikonomou
- 1st Department of Cardiology, 'Hippokration' Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece
| | - Gerasimos Siasos
- 1st Department of Cardiology, 'Hippokration' Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece
| | - Sotiris Tsalamadris
- 1st Department of Cardiology, 'Hippokration' Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece
| | - Georgia Vogiatzi
- 1st Department of Cardiology, 'Hippokration' Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece
| | - Alexios Antonopoulos
- 1st Department of Cardiology, 'Hippokration' Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece
| | - Petros Fountoulakis
- 1st Department of Cardiology, 'Hippokration' Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece
| | - Athina Goliopoulou
- 1st Department of Cardiology, 'Hippokration' Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece
| | - Spyridon Papaioannou
- 1st Department of Cardiology, 'Hippokration' Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece
| | - Dimitris Tousoulis
- 1st Department of Cardiology, 'Hippokration' Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece
| |
Collapse
|
9
|
Chen QF, Liu YY, Pan CS, Fan JY, Yan L, Hu BH, Chang X, Li Q, Han JY. Angioedema and Hemorrhage After 4.5-Hour tPA (Tissue-Type Plasminogen Activator) Thrombolysis Ameliorated by T541 via Restoring Brain Microvascular Integrity. Stroke 2019; 49:2211-2219. [PMID: 30354988 DOI: 10.1161/strokeaha.118.021754] [Citation(s) in RCA: 33] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Background and Purpose- tPA (tissue-type plasminogen activator) is the only recommended intravenous thrombolytic agent for ischemic stroke. However, its application is limited because of increased risk of hemorrhagic transformation beyond the time window. T541 is a Chinese compound medicine with potential to attenuate ischemia and reperfusion injury. This study was to explore whether T541-benefited subjects underwent tPA thrombolysis extending the time window. Methods- Male C57BL/6 N mice were subjected to carotid artery thrombosis by stimulation with 10% FeCl3 followed by 10 mg/kg tPA with/without 20 mg/kg T541 intervention at 4.5 hours. Thrombolysis and cerebral blood flow were observed dynamically until 24 hours after drug treatment. Neurological deficit scores, brain edema and hemorrhage, cerebral microvascular junctions and basement membrane proteins, and energy metabolism in cortex were assessed then. An in vitro hypoxia/reoxygenation model using human cerebral microvascular endothelial cells was used to evaluate effect of T541 on tight junctions and F-actin in the presence of tPA. Results- tPA administered at 4.5 hours after carotid thrombosis resulted in a decrease in thrombus area and survival rate, whereas no benefit on cerebral blood flow. Study at 24 hours after tPA administration revealed a significant angioedema and hemorrhage in the ischemia hemisphere, a decreased expression of junction proteins claudin-5, zonula occludens-1, occludin, junctional adhesion molecule-1 and vascular endothelial cadherin, and collagen IV and laminin. Meanwhile, ADP/ATP, AMP/ATP, and ATP5D (ATP synthase subunit) expression and activities of mitochondria complex I, II, and IV declined, whereas malondialdehyde and 8-Oxo-2'-deoxyguanosine increased and F-actin arrangement disordered. All the insults after tPA treatment were attenuated by addition of T541 dose dependently. Conclusions- The results suggest T541 as a potential remedy to attenuate delayed tPA-related angioedema and hemorrhage and extend time window for tPA treatment. The potential of T541 to upregulate energy metabolism and protect blood-brain barrier is likely attributable to its effects observed.
Collapse
Affiliation(s)
- Qing-Fang Chen
- From the Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University, Beijing, China (Q.-F.C., J.-Y.H.).,Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China (Q.-F.C., Y.-Y.L., C.-S.P., J.-Y.F., L.Y., B.-H.H., X.C., Q.L., J.-Y.H.).,Key Laboratory of Microcirculation (Q.-F.C., Y.-Y.L., C.-S.P., J.-Y.F., L.Y., B.-H.H., X.C., Q.L., J.-Y.H.).,Key Laboratory of Stasis and Phlegm (Q.-F.C., Y.-Y.L., C.-S.P., J.-Y.F., L.Y., B.-H.H., X.C., Q.L., J.-Y.H.).,State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing; State Key Laboratory of Core Technology in Innovative Chinese Medicine, Beijing (Q.-F.C., Y.-Y.L., C.-S.P., J.-Y.F., L.Y., B.-H.H., X.C., Q.L., J.-Y.H.).,Beijing Microvascular Institute of Integration of Chinese and Western Medicine (Q.-F.C., Y.-Y.L., C.-S.P., J.-Y.F., L.Y., B.-H.H., X.C., Q.L., J.-Y.H.)
| | - Yu-Ying Liu
- Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China (Q.-F.C., Y.-Y.L., C.-S.P., J.-Y.F., L.Y., B.-H.H., X.C., Q.L., J.-Y.H.).,Key Laboratory of Microcirculation (Q.-F.C., Y.-Y.L., C.-S.P., J.-Y.F., L.Y., B.-H.H., X.C., Q.L., J.-Y.H.).,Key Laboratory of Stasis and Phlegm (Q.-F.C., Y.-Y.L., C.-S.P., J.-Y.F., L.Y., B.-H.H., X.C., Q.L., J.-Y.H.).,State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing; State Key Laboratory of Core Technology in Innovative Chinese Medicine, Beijing (Q.-F.C., Y.-Y.L., C.-S.P., J.-Y.F., L.Y., B.-H.H., X.C., Q.L., J.-Y.H.).,Beijing Microvascular Institute of Integration of Chinese and Western Medicine (Q.-F.C., Y.-Y.L., C.-S.P., J.-Y.F., L.Y., B.-H.H., X.C., Q.L., J.-Y.H.)
| | - Chun-Shui Pan
- Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China (Q.-F.C., Y.-Y.L., C.-S.P., J.-Y.F., L.Y., B.-H.H., X.C., Q.L., J.-Y.H.).,Key Laboratory of Microcirculation (Q.-F.C., Y.-Y.L., C.-S.P., J.-Y.F., L.Y., B.-H.H., X.C., Q.L., J.-Y.H.).,Key Laboratory of Stasis and Phlegm (Q.-F.C., Y.-Y.L., C.-S.P., J.-Y.F., L.Y., B.-H.H., X.C., Q.L., J.-Y.H.).,State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing; State Key Laboratory of Core Technology in Innovative Chinese Medicine, Beijing (Q.-F.C., Y.-Y.L., C.-S.P., J.-Y.F., L.Y., B.-H.H., X.C., Q.L., J.-Y.H.).,Beijing Microvascular Institute of Integration of Chinese and Western Medicine (Q.-F.C., Y.-Y.L., C.-S.P., J.-Y.F., L.Y., B.-H.H., X.C., Q.L., J.-Y.H.)
| | - Jing-Yu Fan
- Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China (Q.-F.C., Y.-Y.L., C.-S.P., J.-Y.F., L.Y., B.-H.H., X.C., Q.L., J.-Y.H.).,Key Laboratory of Microcirculation (Q.-F.C., Y.-Y.L., C.-S.P., J.-Y.F., L.Y., B.-H.H., X.C., Q.L., J.-Y.H.).,Key Laboratory of Stasis and Phlegm (Q.-F.C., Y.-Y.L., C.-S.P., J.-Y.F., L.Y., B.-H.H., X.C., Q.L., J.-Y.H.).,State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing; State Key Laboratory of Core Technology in Innovative Chinese Medicine, Beijing (Q.-F.C., Y.-Y.L., C.-S.P., J.-Y.F., L.Y., B.-H.H., X.C., Q.L., J.-Y.H.).,Beijing Microvascular Institute of Integration of Chinese and Western Medicine (Q.-F.C., Y.-Y.L., C.-S.P., J.-Y.F., L.Y., B.-H.H., X.C., Q.L., J.-Y.H.)
| | - Li Yan
- Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China (Q.-F.C., Y.-Y.L., C.-S.P., J.-Y.F., L.Y., B.-H.H., X.C., Q.L., J.-Y.H.).,Key Laboratory of Microcirculation (Q.-F.C., Y.-Y.L., C.-S.P., J.-Y.F., L.Y., B.-H.H., X.C., Q.L., J.-Y.H.).,Key Laboratory of Stasis and Phlegm (Q.-F.C., Y.-Y.L., C.-S.P., J.-Y.F., L.Y., B.-H.H., X.C., Q.L., J.-Y.H.).,State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing; State Key Laboratory of Core Technology in Innovative Chinese Medicine, Beijing (Q.-F.C., Y.-Y.L., C.-S.P., J.-Y.F., L.Y., B.-H.H., X.C., Q.L., J.-Y.H.).,Beijing Microvascular Institute of Integration of Chinese and Western Medicine (Q.-F.C., Y.-Y.L., C.-S.P., J.-Y.F., L.Y., B.-H.H., X.C., Q.L., J.-Y.H.)
| | - Bai-He Hu
- Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China (Q.-F.C., Y.-Y.L., C.-S.P., J.-Y.F., L.Y., B.-H.H., X.C., Q.L., J.-Y.H.).,Key Laboratory of Microcirculation (Q.-F.C., Y.-Y.L., C.-S.P., J.-Y.F., L.Y., B.-H.H., X.C., Q.L., J.-Y.H.).,Key Laboratory of Stasis and Phlegm (Q.-F.C., Y.-Y.L., C.-S.P., J.-Y.F., L.Y., B.-H.H., X.C., Q.L., J.-Y.H.).,State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing; State Key Laboratory of Core Technology in Innovative Chinese Medicine, Beijing (Q.-F.C., Y.-Y.L., C.-S.P., J.-Y.F., L.Y., B.-H.H., X.C., Q.L., J.-Y.H.).,Beijing Microvascular Institute of Integration of Chinese and Western Medicine (Q.-F.C., Y.-Y.L., C.-S.P., J.-Y.F., L.Y., B.-H.H., X.C., Q.L., J.-Y.H.)
| | - Xin Chang
- Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China (Q.-F.C., Y.-Y.L., C.-S.P., J.-Y.F., L.Y., B.-H.H., X.C., Q.L., J.-Y.H.).,Key Laboratory of Microcirculation (Q.-F.C., Y.-Y.L., C.-S.P., J.-Y.F., L.Y., B.-H.H., X.C., Q.L., J.-Y.H.).,Key Laboratory of Stasis and Phlegm (Q.-F.C., Y.-Y.L., C.-S.P., J.-Y.F., L.Y., B.-H.H., X.C., Q.L., J.-Y.H.).,State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing; State Key Laboratory of Core Technology in Innovative Chinese Medicine, Beijing (Q.-F.C., Y.-Y.L., C.-S.P., J.-Y.F., L.Y., B.-H.H., X.C., Q.L., J.-Y.H.).,Beijing Microvascular Institute of Integration of Chinese and Western Medicine (Q.-F.C., Y.-Y.L., C.-S.P., J.-Y.F., L.Y., B.-H.H., X.C., Q.L., J.-Y.H.)
| | - Quan Li
- Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China (Q.-F.C., Y.-Y.L., C.-S.P., J.-Y.F., L.Y., B.-H.H., X.C., Q.L., J.-Y.H.).,Key Laboratory of Microcirculation (Q.-F.C., Y.-Y.L., C.-S.P., J.-Y.F., L.Y., B.-H.H., X.C., Q.L., J.-Y.H.).,Key Laboratory of Stasis and Phlegm (Q.-F.C., Y.-Y.L., C.-S.P., J.-Y.F., L.Y., B.-H.H., X.C., Q.L., J.-Y.H.).,State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing; State Key Laboratory of Core Technology in Innovative Chinese Medicine, Beijing (Q.-F.C., Y.-Y.L., C.-S.P., J.-Y.F., L.Y., B.-H.H., X.C., Q.L., J.-Y.H.).,Beijing Microvascular Institute of Integration of Chinese and Western Medicine (Q.-F.C., Y.-Y.L., C.-S.P., J.-Y.F., L.Y., B.-H.H., X.C., Q.L., J.-Y.H.)
| | - Jing-Yan Han
- From the Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University, Beijing, China (Q.-F.C., J.-Y.H.).,Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China (Q.-F.C., Y.-Y.L., C.-S.P., J.-Y.F., L.Y., B.-H.H., X.C., Q.L., J.-Y.H.).,Key Laboratory of Microcirculation (Q.-F.C., Y.-Y.L., C.-S.P., J.-Y.F., L.Y., B.-H.H., X.C., Q.L., J.-Y.H.).,Key Laboratory of Stasis and Phlegm (Q.-F.C., Y.-Y.L., C.-S.P., J.-Y.F., L.Y., B.-H.H., X.C., Q.L., J.-Y.H.).,State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing; State Key Laboratory of Core Technology in Innovative Chinese Medicine, Beijing (Q.-F.C., Y.-Y.L., C.-S.P., J.-Y.F., L.Y., B.-H.H., X.C., Q.L., J.-Y.H.).,Beijing Microvascular Institute of Integration of Chinese and Western Medicine (Q.-F.C., Y.-Y.L., C.-S.P., J.-Y.F., L.Y., B.-H.H., X.C., Q.L., J.-Y.H.)
| |
Collapse
|
10
|
Deng JN, Li Q, Sun K, Pan CS, Li H, Fan JY, Li G, Hu BH, Chang X, Han JY. Cardiotonic Pills Plus Recombinant Human Prourokinase Ameliorates Atherosclerotic Lesions in LDLR -/- Mice. Front Physiol 2019; 10:1128. [PMID: 31551808 PMCID: PMC6747059 DOI: 10.3389/fphys.2019.01128] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2018] [Accepted: 08/15/2019] [Indexed: 11/24/2022] Open
Abstract
Aim This study was to explore the protective effects of cardiotonic pills (CP) or/and recombinant human prourokinase (proUK)on the atherosclerosis and the potential underlying mechanism. Methods and Results Atherosclerosis was induced in LDLR–/– mice by high fat diet contained 20% lard and 0.5% cholesterol. Daily oral administration of CP (130 mg/kg) or/and intravenous injection of proUK (2.5 mg/kg, twice a week) began at 8 weeks after feeding with high fat diet and continued for 4 weeks. CP alone treatment markedly decreased plasma triglyceride, but did not ameliorate atherosclerosis plaque. No effect was observed for proUK alone on any endpoints tested. CP plus proUK induced a significantly reduction in the atherosclerotic lesions, along with decreased levels of total cholesterol, triglyceride in the plasma. CP plus proUK inhibited the elevated hepatic total cholesterol and triglyceride in high fat diet-fed LDLR–/– mice, up-regulating the expressions of ATP-binding cassette gene 5 and 8, and adipose triglyceride lipase. In the aorta, CP plus proUK inhibited the expression of scavenger receptor A and CD36 in LDLR–/– mice. In addition, we observed that systemic inflammation was inhibited, manifested downregulation of plasma macrophage inflammatory protein-1α and intercellular cell adhesion molecule-1. Conclusion CP plus proUK effectively attenuated atherosclerosis plaque in LDLR–/– mice, which is associated with normalizing the lipid metabolism in the liver and aorta, reducing phagocytosis of receptor-mediated modified-LDL uptake and inhibiting systemic inflammation.
Collapse
Affiliation(s)
- Jing-Na Deng
- Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University, Beijing, China.,Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China.,State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.,Key Laboratory of Microcirculation, State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing, China.,Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing, China.,State Key Laboratory of Core Technology in Innovative Chinese Medicine, Tianjin, China
| | - Quan Li
- Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China.,State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.,Key Laboratory of Microcirculation, State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing, China.,Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing, China.,State Key Laboratory of Core Technology in Innovative Chinese Medicine, Tianjin, China
| | - Kai Sun
- Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China.,State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.,Key Laboratory of Microcirculation, State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing, China.,Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing, China.,State Key Laboratory of Core Technology in Innovative Chinese Medicine, Tianjin, China
| | - Chun-Shui Pan
- Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China.,State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.,Key Laboratory of Microcirculation, State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing, China.,Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing, China.,State Key Laboratory of Core Technology in Innovative Chinese Medicine, Tianjin, China
| | - Huan Li
- Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University, Beijing, China.,Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China.,State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.,Key Laboratory of Microcirculation, State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing, China.,Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing, China.,State Key Laboratory of Core Technology in Innovative Chinese Medicine, Tianjin, China
| | - Jing-Yu Fan
- Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China.,State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.,Key Laboratory of Microcirculation, State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing, China.,Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing, China.,State Key Laboratory of Core Technology in Innovative Chinese Medicine, Tianjin, China
| | - Gao Li
- Department of Oncology, Guizhou University of Chinese Medicine, Guiyang, China
| | - Bai-He Hu
- Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China.,State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.,Key Laboratory of Microcirculation, State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing, China.,Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing, China.,State Key Laboratory of Core Technology in Innovative Chinese Medicine, Tianjin, China
| | - Xin Chang
- Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China.,State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.,Key Laboratory of Microcirculation, State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing, China.,Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing, China.,State Key Laboratory of Core Technology in Innovative Chinese Medicine, Tianjin, China
| | - Jing-Yan Han
- Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University, Beijing, China.,Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China.,State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.,Key Laboratory of Microcirculation, State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing, China.,Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing, China.,State Key Laboratory of Core Technology in Innovative Chinese Medicine, Tianjin, China
| |
Collapse
|
11
|
Zheng QN, Wei XH, Pan CS, Li Q, Liu YY, Fan JY, Han JY. QiShenYiQi Pills ® ameliorates ischemia/reperfusion-induced myocardial fibrosis involving RP S19-mediated TGFβ1/Smads signaling pathway. Pharmacol Res 2019; 146:104272. [PMID: 31085230 DOI: 10.1016/j.phrs.2019.104272] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/11/2019] [Revised: 05/03/2019] [Accepted: 05/10/2019] [Indexed: 12/31/2022]
Abstract
QiShenYiQi Pills (QSYQ) is a compound Chinese medicine widely used in China for treatment of cardiovascular disease. However, limited data are available regarding the anti-fibrotic role of QSYQ after ischemia/reperfusion (I/R) injury. This study aimed to investigate the effect of post-treatment with QSYQ on myocardial fibrosis after I/R-induced myocardium injury, and the role of different compounds of QSYQ, focusing especially on the involvement of chemokine ribosomal protein S19 (RP S19) dimer and monocyte migration. Male Sprague-Dawley rats were subjected to left anterior descending coronary artery occlusion for 30 min followed by reperfusion with or without administration of QSYQ (0.6, 1.2, or 1.8 g/kg) once daily by gavage for 6 days. Post-treatment with QSYQ diminished I/R-induced infarct size, alleviated myocardium injury, attenuated myocardial fibrosis after 6 days of reperfusion, and restored heart function and myocardial blood flow after I/R. In addition, the drug significantly inhibited monocyte infiltration and macrophage polarization towards M2, which was attributable to chemokine RP S19 dimer. Moreover, Western blots revealed that QSYQ blocked I/R-induced increase in TGFβ1 and TGFβRⅡ and reversed its relevant gene expression, such as Smad3,4,6,7, and inhibited the increase of MMP 2,9 expression. As the major components of QSYQ, astragaloside IV (AsIV), 3,4-dihydroxy-phenyl lactic acid (DLA), and notoginsenoside R1 (R1) were assessed as to the contribution of each of them to the expression of the proteins concerned. The results showed that the effect of AsIV was similar to QSYQ, while DLA and R1 only partly simulated the effect of QSYQ. The results provide evidence for the potential role of QSYQ in treating myocardial fibrosis following I/R injury. This effect may be associated with QSYQ's inhibition effect on monocyte chemotaxis and TGFβ1/Smads signaling pathway with different component targeting distinct link (s) of the signaling.
Collapse
Affiliation(s)
- Qian-Ning Zheng
- Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University, Beijing, 100191, China; Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, 100191, China; Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing, 100191, China; Beijing Laboratory of Integrative Microangiopathy, Beijing, 100191, China; State Key Laboratory of Core Technology in Innovative Chinese Medicine, Beijing, 100191, China
| | - Xiao-Hong Wei
- Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University, Beijing, 100191, China; Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, 100191, China; Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing, 100191, China; Beijing Laboratory of Integrative Microangiopathy, Beijing, 100191, China; State Key Laboratory of Core Technology in Innovative Chinese Medicine, Beijing, 100191, China
| | - Chun-Shui Pan
- Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, 100191, China; Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing, 100191, China; Beijing Laboratory of Integrative Microangiopathy, Beijing, 100191, China; State Key Laboratory of Core Technology in Innovative Chinese Medicine, Beijing, 100191, China
| | - Quan Li
- Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, 100191, China; Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing, 100191, China; Beijing Laboratory of Integrative Microangiopathy, Beijing, 100191, China; State Key Laboratory of Core Technology in Innovative Chinese Medicine, Beijing, 100191, China
| | - Yu-Ying Liu
- Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, 100191, China; Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing, 100191, China; Beijing Laboratory of Integrative Microangiopathy, Beijing, 100191, China; State Key Laboratory of Core Technology in Innovative Chinese Medicine, Beijing, 100191, China
| | - Jing-Yu Fan
- Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, 100191, China; State Key Laboratory of Core Technology in Innovative Chinese Medicine, Beijing, 100191, China
| | - Jing-Yan Han
- Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University, Beijing, 100191, China; Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, 100191, China; Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing, 100191, China; Beijing Laboratory of Integrative Microangiopathy, Beijing, 100191, China; State Key Laboratory of Core Technology in Innovative Chinese Medicine, Beijing, 100191, China.
| |
Collapse
|
12
|
Liao W, Ma X, Li J, Li X, Guo Z, Zhou S, Sun H. A review of the mechanism of action of Dantonic® for the treatment of chronic stable angina. Biomed Pharmacother 2019; 109:690-700. [DOI: 10.1016/j.biopha.2018.10.013] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2018] [Revised: 09/30/2018] [Accepted: 10/03/2018] [Indexed: 01/04/2023] Open
|
13
|
Sun T, Zhang L, Li X, Chen F, Li Y, Ma X, Yu F. MicroRNA-1 and Circulating Microvesicles Mediate the Protective Effects of Dantonic in Acute Myocardial Infarction Rat Models. Front Physiol 2018; 9:664. [PMID: 30319429 PMCID: PMC6166418 DOI: 10.3389/fphys.2018.00664] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2017] [Accepted: 05/14/2018] [Indexed: 11/13/2022] Open
Abstract
Aim: To investigate the protective effect of dantonic in ischemic myocardial damage by evaluating the expression of circulating microvesicles (MVs) and microRNA-1 (miR-1) in two animal models. Methods: Two animal models of myocardial ischemia were established that were isoproterenol-induced myocardial ischemia (ISO-AMI) rat model and the acute myocardial infarction rat model induced by ligation of the left anterior descending coronary artery (LAD-AMI) of rat. To investigate the protective effect of dantonic, we observed the myocardial infarction size, creatine kinase (CK), lactate dehydrogenase (LDH), aspartate aminotransferase (AST) activities, cardiac troponin I (cTnI) level in serum, and the plasma levels of miR-1 and MVs. Results: The results showed that pretreatment with dantonic significantly attenuated the LAD-AMI induced myocardial damage by decreasing the size of myocardial infarction, CK, LDH, AST activities, and cTnI level in serum. High dose dantonic treatment could significantly abrogate the increased plasma levels of miR-1 and MVs as compared to the LAD rat model. In addition, pretreatment with dantonic also showed a significant myocardial protective effect through reducing the expression levels of CK, LDH, and AST as compared to the ISO-AMI model. Whereas the cTnI level was no significant difference between model group and control group, suggesting that the model caused less myocardial damage. In the ISO-induced myocardial ischemia model, there is no significant difference between the model group with the control group of MVs and miR-1 levels. This may be that miR-1 is reported as a biomarker of acute myocardial infarction. The pathological changes of IOS-induced acute myocardial ischemia model are also different from those of acute myocardial infarction. Conclusion: Dantonic showed the protective effect in these two ischemic myocardial injury rat models, whereas the circulating miR-1 and MVs levels were only ameliorated in the LAD rat model.
Collapse
Affiliation(s)
- Tingting Sun
- School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China.,State Key Laboratory of Core Technology in Innovative Chinese Medicine, Pharmacology and Toxicology Research Centre, Tasly Academy, Tasly Holding Group Co., Ltd., Tianjin, China
| | - Lihua Zhang
- State Key Laboratory of Core Technology in Innovative Chinese Medicine, Pharmacology and Toxicology Research Centre, Tasly Academy, Tasly Holding Group Co., Ltd., Tianjin, China
| | - Xinxin Li
- State Key Laboratory of Core Technology in Innovative Chinese Medicine, Pharmacology and Toxicology Research Centre, Tasly Academy, Tasly Holding Group Co., Ltd., Tianjin, China
| | - Fengfei Chen
- School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China.,State Key Laboratory of Core Technology in Innovative Chinese Medicine, Pharmacology and Toxicology Research Centre, Tasly Academy, Tasly Holding Group Co., Ltd., Tianjin, China
| | - Yanchuan Li
- State Key Laboratory of Core Technology in Innovative Chinese Medicine, Pharmacology and Toxicology Research Centre, Tasly Academy, Tasly Holding Group Co., Ltd., Tianjin, China
| | - Xiaohui Ma
- State Key Laboratory of Core Technology in Innovative Chinese Medicine, Pharmacology and Toxicology Research Centre, Tasly Academy, Tasly Holding Group Co., Ltd., Tianjin, China
| | - Feng Yu
- School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China
| |
Collapse
|
14
|
Li J, Wang B, Zhou G, Yan X, Zhang Y. Tetrahydroxy Stilbene Glucoside Alleviates High Glucose-Induced MPC5 Podocytes Injury Through Suppression of NLRP3 Inflammasome. Am J Med Sci 2018; 355:588-596. [PMID: 29891042 DOI: 10.1016/j.amjms.2018.03.005] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2017] [Revised: 03/01/2018] [Accepted: 03/02/2018] [Indexed: 12/30/2022]
Abstract
BACKGROUND Tetrahydroxy stilbene glucoside (TSG) is an active ingredient of Heshouwu and is an antioxidant. The underlying mechanisms of the renoprotective effect of TSG in diabetic nephropathy have not been previously reported. In this study, we investigated the mechanisms of TSG in preventing podocytes injury in high glucose (HG) condition. METHODS Cultured mouse podocytes (MPC5) were incubated in HG (30mmol/L) plus various concentration of TSG (0.1, 1 and 10μM) for 48 hours. Reactive oxygen species (ROS) production, malondialdehyde (MDA) levels, terminal deoxynucleotidyl-transferase (TdT)-mediated dUTP-biotin nick end-labeling (TUNEL) fluorescence intensity, caspase-3 activity and the mRNA expression of nephrin in cultured podocytes were determined. The protein expression of Nod-like receptor protein 3 (NLRP3) inflammsome, interleukin-1β (IL-1β) and nephrin was detected by Western blot. RESULTS When the podocytes were incubated with various concentrations of TSG under HG conditions for 48 hours, TSG decreased ROS production, MDA levels, TUNEL fluorescence intensity and caspase-3 activity, but increased cell viability and the expression of nephrin in HG-induced podocytes in a dose-dependent manner. Subsequently, the podocytes treated with TSG at 10 μΜ decreased the expression of NLRP3 inflammasome and IL-1β compared with that of control. Furthermore, the podocytes transfected with NLRP3- small interfering RNA (siRNA) exhibited a significant decrease in the expression of caspase-1 and IL-1β, but exhibited a significant increase in the expression of nephrin. Eventually, TSG significantly increased the expression of nephrin in IL-1β-treated podocytes. CONCLUSIONS TSG attenuates high glucose-induced cell apoptosis in vitro partly through the suppression of NLRP3 inflammasome signaling.
Collapse
Affiliation(s)
- Jinfeng Li
- Department of Pharmacy, Weihai Municipal Hospital, 264200, Weihai, Shandong Province, China
| | - Bing Wang
- Department of Pharmacy, Weihai Municipal Hospital, 264200, Weihai, Shandong Province, China
| | - Guangjie Zhou
- Department of Pharmacy, Weihai Municipal Hospital, 264200, Weihai, Shandong Province, China
| | - Xiujuan Yan
- Department of Pharmacy, Weihai Municipal Hospital, 264200, Weihai, Shandong Province, China
| | - Yuan Zhang
- Department of Pharmacy, Weihai Municipal Hospital, 264200, Weihai, Shandong Province, China.
| |
Collapse
|
15
|
Han JY, Li Q, Ma ZZ, Fan JY. Effects and mechanisms of compound Chinese medicine and major ingredients on microcirculatory dysfunction and organ injury induced by ischemia/reperfusion. Pharmacol Ther 2017; 177:146-173. [PMID: 28322971 DOI: 10.1016/j.pharmthera.2017.03.005] [Citation(s) in RCA: 105] [Impact Index Per Article: 15.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Microcirculation dysfunction and organ injury after ischemia and reperfusion (I/R) result from a complex pathologic process consisting of multiple links, with metabolism impairment in the ischemia phase and oxidative stress in the reperfusion phase as initiators, and any treatment targeting a single link is insufficient to cope with this. Compound Chinese medicine (CCM) has been applied in clinics in China and some Asian nations for >2000years. Studies over the past decades revealed the protective and therapeutic effect of CCMs and major ingredients on I/R-induced microcirculatory dysfunction and tissue injury in the heart, brain, liver, intestine, and so on. CCM contains diverse bioactive components with potential for energy metabolism regulation; antioxidant effect; inhibiting inflammatory cytokines release; adhesion molecule expression in leukocyte, platelet, and vascular endothelial cells; and the protection of thrombosis, albumin leakage, and mast cell degranulation. This review covers the major works with respect to the effects and underlying mechanisms of CCM and its ingredients on microcirculatory dysfunction and organ injury after I/R, providing novel ideas for dealing with this threat.
Collapse
Affiliation(s)
- Jing-Yan Han
- Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University, Beijing 100191, China; Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing 100191, China; Key Laboratory of Microcirculation, State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing 100191, China; Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing 100191, China; Beijing Microvascular Institute of Integration of Chinese and Western Medicine, Beijing, China.
| | - Quan Li
- Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing 100191, China; Key Laboratory of Microcirculation, State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing 100191, China; Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing 100191, China; Beijing Microvascular Institute of Integration of Chinese and Western Medicine, Beijing, China
| | - Zhi-Zhong Ma
- Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University, Beijing 100191, China
| | - Jing-Yu Fan
- Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing 100191, China; Key Laboratory of Microcirculation, State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing 100191, China; Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing 100191, China; Beijing Microvascular Institute of Integration of Chinese and Western Medicine, Beijing, China
| |
Collapse
|
16
|
Guo J, Yong Y, Aa J, Cao B, Sun R, Yu X, Huang J, Yang N, Yan L, Li X, Cao J, Aa N, Yang Z, Kong X, Wang L, Zhu X, Ma X, Guo Z, Zhou S, Sun H, Wang G. Compound danshen dripping pills modulate the perturbed energy metabolism in a rat model of acute myocardial ischemia. Sci Rep 2016; 6:37919. [PMID: 27905409 PMCID: PMC5131350 DOI: 10.1038/srep37919] [Citation(s) in RCA: 46] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2015] [Accepted: 11/02/2016] [Indexed: 01/14/2023] Open
Abstract
The continuous administration of compound danshen dripping pills (CDDP) showed good efficacy in relieving myocardial ischemia clinically. To probe the underlying mechanism, metabolic features were evaluated in a rat model of acute myocardial ischemia induced by isoproterenol (ISO) and administrated with CDDP using a metabolomics platform. Our data revealed that the ISO-induced animal model showed obvious myocardial injury, decreased energy production, and a marked change in metabolomic patterns in plasma and heart tissue. CDDP pretreatment increased energy production, ameliorated biochemical indices, modulated the changes and metabolomic pattern induced by ISO, especially in heart tissue. For the first time, we found that ISO induced myocardial ischemia was accomplished with a reduced fatty acids metabolism and an elevated glycolysis for energy supply upon the ischemic stress; while CDDP pretreatment prevented the tendency induced by ISO and enhanced a metabolic shift towards fatty acids metabolism that conventionally dominates energy supply to cardiac muscle cells. These data suggested that the underlying mechanism of CDDP involved regulating the dominant energy production mode and enhancing a metabolic shift toward fatty acids metabolism in ischemic heart. It was further indicated that CDDP had the potential to prevent myocardial ischemia in clinic.
Collapse
Affiliation(s)
- Jiahua Guo
- Key Laboratory of Drug Metabolism and Pharmacokinetics, State Key Laboratory of Natural Medicines, Key laboratory of drug design and optimization, China Pharmaceutical University, No. 24 TongjiaLane, Nanjing, 210009, China
- State Key Laboratory of Core Technology in Innovative Chinese Medicine, Tasly R&D Institute, Tianjin Tasly Group Co., Ltd., No. 2 Pujihe East Road, Tianjin, 300410, China
| | - Yonghong Yong
- Department of Cardiology, The First Affiliated Hospital of Nanjing Medical University, No. 300 Guangzhou Avenue, Nanjing, 210029, China
| | - Jiye Aa
- Key Laboratory of Drug Metabolism and Pharmacokinetics, State Key Laboratory of Natural Medicines, Key laboratory of drug design and optimization, China Pharmaceutical University, No. 24 TongjiaLane, Nanjing, 210009, China
| | - Bei Cao
- Key Laboratory of Drug Metabolism and Pharmacokinetics, State Key Laboratory of Natural Medicines, Key laboratory of drug design and optimization, China Pharmaceutical University, No. 24 TongjiaLane, Nanjing, 210009, China
| | - Runbin Sun
- Key Laboratory of Drug Metabolism and Pharmacokinetics, State Key Laboratory of Natural Medicines, Key laboratory of drug design and optimization, China Pharmaceutical University, No. 24 TongjiaLane, Nanjing, 210009, China
| | - Xiaoyi Yu
- Key Laboratory of Drug Metabolism and Pharmacokinetics, State Key Laboratory of Natural Medicines, Key laboratory of drug design and optimization, China Pharmaceutical University, No. 24 TongjiaLane, Nanjing, 210009, China
| | - Jingqiu Huang
- Key Laboratory of Drug Metabolism and Pharmacokinetics, State Key Laboratory of Natural Medicines, Key laboratory of drug design and optimization, China Pharmaceutical University, No. 24 TongjiaLane, Nanjing, 210009, China
| | - Na Yang
- Key Laboratory of Drug Metabolism and Pharmacokinetics, State Key Laboratory of Natural Medicines, Key laboratory of drug design and optimization, China Pharmaceutical University, No. 24 TongjiaLane, Nanjing, 210009, China
| | - Lulu Yan
- State Key Laboratory of Core Technology in Innovative Chinese Medicine, Tasly R&D Institute, Tianjin Tasly Group Co., Ltd., No. 2 Pujihe East Road, Tianjin, 300410, China
| | - Xinxin Li
- State Key Laboratory of Core Technology in Innovative Chinese Medicine, Tasly R&D Institute, Tianjin Tasly Group Co., Ltd., No. 2 Pujihe East Road, Tianjin, 300410, China
| | - Jing Cao
- State Key Laboratory of Core Technology in Innovative Chinese Medicine, Tasly R&D Institute, Tianjin Tasly Group Co., Ltd., No. 2 Pujihe East Road, Tianjin, 300410, China
| | - Nan Aa
- Department of Cardiology, The First Affiliated Hospital of Nanjing Medical University, No. 300 Guangzhou Avenue, Nanjing, 210029, China
| | - Zhijian Yang
- Department of Cardiology, The First Affiliated Hospital of Nanjing Medical University, No. 300 Guangzhou Avenue, Nanjing, 210029, China
| | - Xiangqing Kong
- Department of Cardiology, The First Affiliated Hospital of Nanjing Medical University, No. 300 Guangzhou Avenue, Nanjing, 210029, China
| | - Liansheng Wang
- Department of Cardiology, The First Affiliated Hospital of Nanjing Medical University, No. 300 Guangzhou Avenue, Nanjing, 210029, China
| | - Xuanxuan Zhu
- Key Lab of Chinese Medicine, Nanjing University of Chinese Medicine, No. 282 Hanzhong Road, Nanjing, 210029, China
| | - Xiaohui Ma
- State Key Laboratory of Core Technology in Innovative Chinese Medicine, Tasly R&D Institute, Tianjin Tasly Group Co., Ltd., No. 2 Pujihe East Road, Tianjin, 300410, China
- School of Pharmaceutical Science and Technology, Tianjin University, No. 92 Weijin Road, Tianjin, 300072, China
| | - Zhixin Guo
- State Key Laboratory of Core Technology in Innovative Chinese Medicine, Tasly R&D Institute, Tianjin Tasly Group Co., Ltd., No. 2 Pujihe East Road, Tianjin, 300410, China
| | - Shuiping Zhou
- State Key Laboratory of Core Technology in Innovative Chinese Medicine, Tasly R&D Institute, Tianjin Tasly Group Co., Ltd., No. 2 Pujihe East Road, Tianjin, 300410, China
| | - He Sun
- State Key Laboratory of Core Technology in Innovative Chinese Medicine, Tasly R&D Institute, Tianjin Tasly Group Co., Ltd., No. 2 Pujihe East Road, Tianjin, 300410, China
- School of Pharmaceutical Science and Technology, Tianjin University, No. 92 Weijin Road, Tianjin, 300072, China
| | - Guangji Wang
- Key Laboratory of Drug Metabolism and Pharmacokinetics, State Key Laboratory of Natural Medicines, Key laboratory of drug design and optimization, China Pharmaceutical University, No. 24 TongjiaLane, Nanjing, 210009, China
| |
Collapse
|
17
|
Yang N, Liu YY, Pan CS, Sun K, Wei XH, Mao XW, Lin F, Li XJ, Fan JY, Han JY. Pretreatment with andrographolide pills(®) attenuates lipopolysaccharide-induced pulmonary microcirculatory disturbance and acute lung injury in rats. Microcirculation 2015; 21:703-16. [PMID: 24919947 DOI: 10.1111/micc.12152] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2013] [Accepted: 06/05/2014] [Indexed: 12/21/2022]
Abstract
OBJECTIVE The purpose of this study was to explore the protective effect of AP on LPS-induced PMD and ALI. METHODS Male SD rats were continuously infused with LPS (5 mg/kg/h) for one hour to induce PMD and ALI. AP was administrated orally one hour before LPS exposure. Arterial blood pressure and HR were monitored. Blood gas analysis, histological observation, cytokines in plasma, leukocyte recruitment, pulmonary oxidative stress, microvessel permeability, edema, and related proteins were evaluated six hours after LPS challenge. RESULTS Rats receiving LPS exhibited significant alterations, including hypotension, tachycardia, increase in cytokines, neutrophil adhesion and infiltration, oxidative stress, and microvessel hyperpermeability, resulting in pulmonary injury and dysfunction. AP (0.18 g/kg or 1.8 g/kg) improved rat survival rate, and significantly attenuated all aforementioned insults, and inhibited LPS-induced increase in adhesion molecules, up-regulation of Cav-1 and Src kinase and NADPH oxidase subunits (p47(phox) and p67(phox) ) membrane translocation in lung tissue, and preserved JAM-1 and claudin-5. CONCLUSIONS The results demonstrated the protective effect of AP on LPS-induced PMD and ALI, suggesting the potential of AP as a prophylactic strategy for LPS-induced ALI.
Collapse
Affiliation(s)
- Ning Yang
- Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China; Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University, Beijing, China; Department of Pharmacology, School of Basic Medical Sciences, Peking University, Beijing, China; Key Laboratory of Microcirculation, State Administration of Traditional Chinese Medicine of China, Beijing, China
| | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Tang H, Pan CS, Mao XW, Liu YY, Yan L, Zhou CM, Fan JY, Zhang SY, Han JY. Role of NADPH oxidase in total salvianolic acid injection attenuating ischemia-reperfusion impaired cerebral microcirculation and neurons: implication of AMPK/Akt/PKC. Microcirculation 2015; 21:615-27. [PMID: 24702968 DOI: 10.1111/micc.12140] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2014] [Accepted: 04/02/2014] [Indexed: 11/30/2022]
Abstract
OBJECTIVE TSI is a new drug derived from Chinese medicine for treatment of ischemic stroke in China. The aim of this study was to verify the therapeutic effect of TSI in a rat model of MCAO, and further explore the mechanism for its effect. METHODS Male Sprague-Dawley rats were subjected to right MCAO for 60 minutes followed by reperfusion. TSI (1.67 mg/kg) was administrated before reperfusion via femoral vein injection. Twenty-four hours after reperfusion, the fluorescence intensity of DHR 123 in, leukocyte adhesion to and albumin leakage from the cerebral venules were observed. Neurological scores, TTC staining, brain water content, Nissl staining, TUNEL staining, and MDA content were assessed. Bcl-2/Bax, cleaved caspase-3, NADPH oxidase subunits p47(phox)/p67(phox)/gp91(phox), and AMPK/Akt/PKC were analyzed by Western blot. RESULTS TSI attenuated I/R-induced microcirculatory disturbance and neuron damage, activated AMPK, inhibited NADPH oxidase subunits membrane translocation, suppressed Akt phosphorylation, and PKC translocation. CONCLUSIONS TSI attenuates I/R-induced brain injury in rats, supporting its clinic use for treatment of acute ischemic stroke. The role of TSI may benefit from its antioxidant activity, which is most likely implemented via inactivation of NADPH oxidase through a signaling pathway implicating AMPK/Akt/PKC.
Collapse
Affiliation(s)
- Hao Tang
- The Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China
| | | | | | | | | | | | | | | | | |
Collapse
|
19
|
3, 4-dihydroxyl-phenyl lactic acid restores NADH dehydrogenase 1 α subunit 10 to ameliorate cardiac reperfusion injury. Sci Rep 2015; 5:10739. [PMID: 26030156 PMCID: PMC5377067 DOI: 10.1038/srep10739] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2014] [Accepted: 04/27/2015] [Indexed: 01/16/2023] Open
Abstract
The present study aimed to detect the role of 3, 4-dihydroxyl-phenyl lactic acid (DLA) during ischemia/reperfusion (I/R) induced myocardial injury with emphasis on the underlying mechanism of DLA antioxidant. Male Spragu-Dawley (SD) rats were subjected to left descending artery occlusion followed by reperfusion. Treatment with DLA ameliorated myocardial structure and function disorder, blunted the impairment of Complex I activity and mitochondrial function after I/R. The results of 2-D fluorescence difference gel electrophoresis revealed that DLA prevented the decrease in NDUFA10 expression, one of the subunits of Complex I. To find the target of DLA, the binding affinity of Sirtuin 1 (SIRT1) to DLA and DLA derivatives with replaced two phenolic hydroxyls was detected using surface plasmon resonance and bilayer interferometry. The results showed that DLA could activate SIRT1 after I/R probably by binding to this protein, depending on phenolic hydroxyl. Moreover, the importance of SIRT1 to DLA effectiveness was confirmed through siRNA transfection in vitro. These results demonstrated that DLA was able to prevent I/R induced decrease in NDUFA10 expression, improve Complex I activity and mitochondrial function, eventually attenuate cardiac structure and function injury after I/R, which was possibly related to its ability of binding to and activating SIRT1.
Collapse
|
20
|
Pan CS, Liu YH, Liu YY, Zhang Y, He K, Yang XY, Hu BH, Chang X, Wang MX, Wei XH, Fan JY, Wu XM, Han JY. Salvianolic Acid B Ameliorates Lipopolysaccharide-Induced Albumin Leakage from Rat Mesenteric Venules through Src-Regulated Transcelluar Pathway and Paracellular Pathway. PLoS One 2015; 10:e0126640. [PMID: 25992563 PMCID: PMC4438061 DOI: 10.1371/journal.pone.0126640] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2014] [Accepted: 04/05/2015] [Indexed: 12/15/2022] Open
Abstract
Lipopolysaccharide (LPS) causes microvascular barrier disruption, leading to albumin leakage from microvessels resulting in a range of disastrous sequels. Salvianolic acid B (SalB) is a major water-soluble component derived from Salvia miltiorrhiza. Previous studies showed its potential to attenuate microvascular barrier dysfunction, but the underlying mechanism is not fully understood. The present study was intended to investigate the impact of SalB on endothelial cell barrier in vivo in rat mesenteric venules as well as in vitro in human umbilical vein endothelial cells (HUVECs), aiming at disclosing the mechanism thereof, particularly the role of Src in its action. Male Wistar rats were challenged by infusion of LPS (2 mg/kg/h) through left femoral vein for 90 min. SalB (5 mg/kg/h) was administrated either simultaneously with LPS or 30 min after LPS infusion through the left jugular vein. Vesicles in venular walls were observed by electron microscopy. HUVECs were incubated with LPS with or without SalB. The expression of Zonula occluden-1 (ZO-1), VE-cadherin, caveolin-1 and Src in HUVECs was assessed by Western blot and confocal microscopy, binding of SalB to Src was measured using Surface Plasmon Resonance and BioLayer Interferometry. Treatment with SalB inhibited albumin leakage from rat mesenteric venules and inhibited the increase of vesicle number in venular endothelial cells induced by LPS. In addition, SalB inhibited the degradation of ZO-1, the phosphorylation and redistribution of VE-cadherin, the expression and phosphorylation of caveolin-1, and phosphoirylation of Src in HUVECs exposed to LPS. Furthermore, SalB was found able to bind to Src. This study demonstrates that protection of SalB against microvascular barrier disruption is a process involving both para- and trans-endothelial cell pathway, and highly suggests Src as the key enzyme for SalB to work.
Collapse
Affiliation(s)
- Chun-Shui Pan
- Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China
- Key Laboratory of Microcirculation, State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing, China
- Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing, China
| | - Ying-Hua Liu
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital& Institute, Beijing, China
| | - Yu-Ying Liu
- Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China
- Key Laboratory of Microcirculation, State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing, China
- Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing, China
| | - Yu Zhang
- Department of Integration of Traditional Chinese and Western Medicine, School of Basic Medical Sciences, Peking University, Beijing, China
- Key Laboratory of Microcirculation, State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing, China
- Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing, China
| | - Ke He
- Department of Integration of Traditional Chinese and Western Medicine, School of Basic Medical Sciences, Peking University, Beijing, China
- Key Laboratory of Microcirculation, State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing, China
- Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing, China
| | - Xiao-Yuan Yang
- Department of Integration of Traditional Chinese and Western Medicine, School of Basic Medical Sciences, Peking University, Beijing, China
- Key Laboratory of Microcirculation, State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing, China
- Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing, China
| | - Bai-He Hu
- Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China
- Key Laboratory of Microcirculation, State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing, China
- Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing, China
| | - Xin Chang
- Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China
- Key Laboratory of Microcirculation, State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing, China
- Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing, China
| | - Ming-Xia Wang
- Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China
- Key Laboratory of Microcirculation, State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing, China
- Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing, China
| | - Xiao-Hong Wei
- Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China
| | - Jing-Yu Fan
- Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China
| | - Xin-Min Wu
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital& Institute, Beijing, China
| | - Jing-Yan Han
- Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China
- Department of Integration of Traditional Chinese and Western Medicine, School of Basic Medical Sciences, Peking University, Beijing, China
- Key Laboratory of Microcirculation, State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing, China
- Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing, China
- * E-mail:
| |
Collapse
|
21
|
Yin Q, Lu H, Bai Y, Tian A, Yang Q, Wu J, Yang C, Fan TP, Zhang Y, Zheng X, Zheng X, Li Z. A metabolite of Danshen formulae attenuates cardiac fibrosis induced by isoprenaline, via a NOX2/ROS/p38 pathway. Br J Pharmacol 2015; 172:5573-85. [PMID: 25766073 DOI: 10.1111/bph.13133] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2014] [Revised: 03/04/2015] [Accepted: 03/05/2015] [Indexed: 12/17/2022] Open
Abstract
BACKGROUND AND PURPOSE Cardiac fibrosis is a common feature of advanced coronary heart disease and is characteristic of heart disease. However, currently available drugs against cardiac fibrosis are still very limited. Here, we have assessed the role of isopropyl 3-(3,4-dihydroxyphenyl)-2-hydroxylpropanoate (IDHP), a new metabolite of Danshen Dripping Pills, in cardiac fibrosis mediated by the β-adrenoceptor agonist, isoprenaline, and its underlying mechanisms. EXPERIMENTAL APPROACH Identification of IDHP was identified by mass spectrometry, and proton and carbon nuclear magnetic resonance spectra. Myocardial collagen was quantitatively assessed with Picrosirius Red staining. Expression of mRNA for collagen was evaluated with real-time PCR. Phosphorylated and total p38 MAPK, NADPH oxidase (NOX) and superoxide dismutase (SOD) were analysed by Western blot. Generation of reactive oxygen species (ROS) generation was evaluated by dihydroethidium (DHE) fluorescent staining. NOX2 was knocked down using specific siRNA. KEY RESULTS IDHP attenuated β-adrenoceptor mediated cardiac fibrosis in vivo and inhibited isoprenaline-induced proliferation of neonatal rat cardiac fibroblasts (NRCFs) and collagen I synthesis in vitro. Phosphorylation of p38 MAPK, which is an important mediator in the pathogenesis of isoprenaline-induced cardiac fibrosis, was inhibited by IDHP. This inhibition of phospho-p38 by IDHP was dependent on decreased generation of ROS. These effects of IDHP were abolished in NRCFs treated with siRNA for NOX2. CONCLUSIONS AND IMPLICATIONS IDHP attenuated the cardiac fibrosis induced by isoprenaline through a NOX2/ROS/p38 pathway. These novel findings suggest that IDHP is a potential pharmacological candidate for the treatment of cardiac fibrosis, induced by β-adrenoceptor agonists.
Collapse
Affiliation(s)
- Qian Yin
- Institute of Vascular Medicine, Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Ministry of Health, Key Laboratory of Molecular Cardiovascular Sciences, Ministry of Education and Beijing Key Laboratory of Cardiovascular Receptors Research, Peking University Third Hospital, Beijing, China.,Department of Cardiovascular Medicine, The First Affiliated Hospital of Xi'an Jiaotong University Health Science Center, Xi'an, China
| | - Haiyan Lu
- Institute of Vascular Medicine, Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Ministry of Health, Key Laboratory of Molecular Cardiovascular Sciences, Ministry of Education and Beijing Key Laboratory of Cardiovascular Receptors Research, Peking University Third Hospital, Beijing, China.,Key Laboratory of Resource Biology and Biotechnology in Western China, Ministry of Education, College of Life Sciences, Northwest University, Xi'an, China
| | - Yajun Bai
- Key Laboratory of Resource Biology and Biotechnology in Western China, Ministry of Education, College of Life Sciences, Northwest University, Xi'an, China
| | - Aiju Tian
- Institute of Vascular Medicine, Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Ministry of Health, Key Laboratory of Molecular Cardiovascular Sciences, Ministry of Education and Beijing Key Laboratory of Cardiovascular Receptors Research, Peking University Third Hospital, Beijing, China
| | - Qiuxiang Yang
- Institute of Vascular Medicine, Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Ministry of Health, Key Laboratory of Molecular Cardiovascular Sciences, Ministry of Education and Beijing Key Laboratory of Cardiovascular Receptors Research, Peking University Third Hospital, Beijing, China.,Key Laboratory of Resource Biology and Biotechnology in Western China, Ministry of Education, College of Life Sciences, Northwest University, Xi'an, China
| | - Jimin Wu
- Institute of Vascular Medicine, Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Ministry of Health, Key Laboratory of Molecular Cardiovascular Sciences, Ministry of Education and Beijing Key Laboratory of Cardiovascular Receptors Research, Peking University Third Hospital, Beijing, China
| | - Chengzhi Yang
- Institute of Vascular Medicine, Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Ministry of Health, Key Laboratory of Molecular Cardiovascular Sciences, Ministry of Education and Beijing Key Laboratory of Cardiovascular Receptors Research, Peking University Third Hospital, Beijing, China
| | - Tai-Ping Fan
- Angiogenesis and Chinese Medicine Laboratory, Department of Pharmacology, University of Cambridge, Cambridge, UK
| | - Youyi Zhang
- Institute of Vascular Medicine, Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Ministry of Health, Key Laboratory of Molecular Cardiovascular Sciences, Ministry of Education and Beijing Key Laboratory of Cardiovascular Receptors Research, Peking University Third Hospital, Beijing, China
| | - Xiaohui Zheng
- Key Laboratory of Resource Biology and Biotechnology in Western China, Ministry of Education, College of Life Sciences, Northwest University, Xi'an, China
| | - Xiaopu Zheng
- Department of Cardiovascular Medicine, The First Affiliated Hospital of Xi'an Jiaotong University Health Science Center, Xi'an, China
| | - Zijian Li
- Institute of Vascular Medicine, Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Ministry of Health, Key Laboratory of Molecular Cardiovascular Sciences, Ministry of Education and Beijing Key Laboratory of Cardiovascular Receptors Research, Peking University Third Hospital, Beijing, China
| |
Collapse
|
22
|
Induction of autophagy by Tongxinluo through the MEK/ERK pathway protects human cardiac microvascular endothelial cells from hypoxia/reoxygenation injury. J Cardiovasc Pharmacol 2015; 64:180-90. [PMID: 24705173 DOI: 10.1097/fjc.0000000000000104] [Citation(s) in RCA: 46] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
: In contrast to cardiomyocytes, autophagy in cardiac microvascular endothelial cells (CMECs) during ischemia/reperfusion (I/R) injury has not been fully investigated. Tongxinluo (TXL), a traditional Chinese medicine, was shown to be vascular protective. We aimed to elucidate the role of autophagy and its regulatory mechanisms by TXL in CMECs subjected to I/R injury. CMECs were exposed to different treatments for 30 minutes and subjected to hypoxia/reoxygenation each for 2 hours. The results indicated that hypoxia/reoxygenation significantly induced autophagy, as identified by an increased number of monodansylcadaverine-positive CMECs, increased autophagosome formation, and a higher type II/type I of light chain 3 ratio, but not Beclin-1 expression. Autophagy inhibition using 3-methyladenine was proapoptotic, but rapamycin-induced autophagy was antiapoptotic. TXL enhanced autophagy and decreased apoptosis in a dose-dependent manner, reaching its largest effect at 800 μg/mL. 3-methyladenine attenuated the TXL-promoted autophagy and antiapoptotic effects, whereas rapamycin had no additional effects compared with TXL alone. TXL upregulated mitogen-activated protein kinase and extracellular signal-regulated kinase (ERK) phosphorylation; however, PD98059 abrogated ERK phosphorylation and decreased autophagy and increased apoptosis compared with TXL alone. These results suggest that autophagy is a protective mechanism in CMECs subjected to I/R injury and that TXL can promote autophagy through activation of the mitogen-activated protein kinase/ERK pathway.
Collapse
|
23
|
Ma LQ, Pan CS, Yang N, Liu YY, Yan L, Sun K, Wei XH, He K, Xiao MM, Fan JY, Han JY. Posttreatment with Ma-Xing-Shi-Gan-Tang, a Chinese Medicine Formula, Ameliorates Lipopolysaccharide-Induced Lung Microvessel Hyperpermeability and Inflammatory Reaction in Rat. Microcirculation 2014; 21:649-63. [DOI: 10.1111/micc.12144] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2014] [Accepted: 05/01/2014] [Indexed: 01/08/2023]
Affiliation(s)
- Li-Qian Ma
- Department of Integration of Chinese and Western Medicine; School of Basic Medical Sciences; Peking University; Beijing China
- Tasly Microcirculation Research Center; Peking University Health Science Center; Beijing China
- Key Laboratory of Microcirculation; State Administration of Traditional Chinese Medicine of China; Beijing China
- Key Laboratory of Stasis and Phlegm; State Administration of Traditional Chinese Medicine of China; Beijing China
| | - Chun-Shui Pan
- Tasly Microcirculation Research Center; Peking University Health Science Center; Beijing China
- Key Laboratory of Microcirculation; State Administration of Traditional Chinese Medicine of China; Beijing China
- Key Laboratory of Stasis and Phlegm; State Administration of Traditional Chinese Medicine of China; Beijing China
| | - Ning Yang
- Tasly Microcirculation Research Center; Peking University Health Science Center; Beijing China
- Key Laboratory of Microcirculation; State Administration of Traditional Chinese Medicine of China; Beijing China
- Key Laboratory of Stasis and Phlegm; State Administration of Traditional Chinese Medicine of China; Beijing China
| | - Yu-Ying Liu
- Tasly Microcirculation Research Center; Peking University Health Science Center; Beijing China
- Key Laboratory of Microcirculation; State Administration of Traditional Chinese Medicine of China; Beijing China
- Key Laboratory of Stasis and Phlegm; State Administration of Traditional Chinese Medicine of China; Beijing China
| | - Li Yan
- Tasly Microcirculation Research Center; Peking University Health Science Center; Beijing China
- Key Laboratory of Microcirculation; State Administration of Traditional Chinese Medicine of China; Beijing China
- Key Laboratory of Stasis and Phlegm; State Administration of Traditional Chinese Medicine of China; Beijing China
| | - Kai Sun
- Tasly Microcirculation Research Center; Peking University Health Science Center; Beijing China
- Key Laboratory of Microcirculation; State Administration of Traditional Chinese Medicine of China; Beijing China
- Key Laboratory of Stasis and Phlegm; State Administration of Traditional Chinese Medicine of China; Beijing China
| | - Xiao-Hong Wei
- Tasly Microcirculation Research Center; Peking University Health Science Center; Beijing China
- Key Laboratory of Microcirculation; State Administration of Traditional Chinese Medicine of China; Beijing China
- Key Laboratory of Stasis and Phlegm; State Administration of Traditional Chinese Medicine of China; Beijing China
| | - Ke He
- Department of Integration of Chinese and Western Medicine; School of Basic Medical Sciences; Peking University; Beijing China
- Tasly Microcirculation Research Center; Peking University Health Science Center; Beijing China
- Key Laboratory of Microcirculation; State Administration of Traditional Chinese Medicine of China; Beijing China
- Key Laboratory of Stasis and Phlegm; State Administration of Traditional Chinese Medicine of China; Beijing China
| | - Meng-Meng Xiao
- Department of Integration of Chinese and Western Medicine; School of Basic Medical Sciences; Peking University; Beijing China
- Tasly Microcirculation Research Center; Peking University Health Science Center; Beijing China
- Key Laboratory of Microcirculation; State Administration of Traditional Chinese Medicine of China; Beijing China
- Key Laboratory of Stasis and Phlegm; State Administration of Traditional Chinese Medicine of China; Beijing China
| | - Jing-Yu Fan
- Tasly Microcirculation Research Center; Peking University Health Science Center; Beijing China
- Key Laboratory of Microcirculation; State Administration of Traditional Chinese Medicine of China; Beijing China
- Key Laboratory of Stasis and Phlegm; State Administration of Traditional Chinese Medicine of China; Beijing China
| | - Jing-Yan Han
- Department of Integration of Chinese and Western Medicine; School of Basic Medical Sciences; Peking University; Beijing China
- Tasly Microcirculation Research Center; Peking University Health Science Center; Beijing China
- Key Laboratory of Microcirculation; State Administration of Traditional Chinese Medicine of China; Beijing China
- Key Laboratory of Stasis and Phlegm; State Administration of Traditional Chinese Medicine of China; Beijing China
| |
Collapse
|
24
|
Hao HF, Liu LM, Liu YY, Liu J, Yan L, Pan CS, Wang MX, Wang CS, Fan JY, Gao YS, Han JY. Inhibitory effect of rhynchophylline on contraction of cerebral arterioles to endothelin 1: role of rho kinase. JOURNAL OF ETHNOPHARMACOLOGY 2014; 155:147-153. [PMID: 24814318 DOI: 10.1016/j.jep.2014.04.050] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/12/2013] [Revised: 04/13/2014] [Accepted: 04/28/2014] [Indexed: 06/03/2023]
Abstract
ETHNOPHARMACOLOGICAL RELEVANCE Rhynchophylline (Rhy) is a major ingredient of Uncaria rhynchophylla (UR) used to reduce blood pressure and ameliorate brain ailments. This study was to examine the role of Rho kinase (ROCK) in the inhibition of Rhy on contraction of cerebral arterioles caused by endothelin 1 (ET-1). MATERIALS AND METHODS Cerebral arterioles of male Wistar rats were constricted with ET-1 for 10 min followed by perfusion of Rhy for 20 min. Changes in the diameters of the arterioles were recorded. The effects of Rhy on contraction of middle cerebral arteries (MCAs) were determined by a Multi-Myograph. Western blotting and immunofluorescent staining were used to examine the effects of Rhy on RhoA translocation and myosin phosphatase target subunit 1 (MYPT1) phosphorylation. RESULTS In vivo, Rhy (30-300 µM) relaxed cerebral arterioles constricted with ET-1 dose-dependently. In vitro, Rhy at lower concentrations (1-100 µM) caused relaxation of rat MCAs constricted with KCl and Bay-K8644 (an agonist of L-type voltage-dependent calcium channels (L-VDCCs)). Rhy at higher concentrations (>100 µM) caused relaxation of rat MCAs constricted with ET-1, which was inhibited by Y27632, a ROCK׳s inhibitor. Western blotting of rat aortas showed that Rhy inhibited RhoA translocation and MYPT1 phosphorylation. Immunofluorescent staining of MCAs confirmed that phosphorylation of MYPT1 caused by ET-1 was inhibited by Rhy. CONCLUSIONS These results demonstrate that Rhy is a potent inhibitor of contraction of cerebral arteries caused by ET-1 in vivo and in vitro. The effect of Rhy was in part mediated by inhibiting RhoA-ROCK signaling.
Collapse
Affiliation(s)
- Hui-Feng Hao
- Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing 100191, China; Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University, 38 Xue Yuan Road, Beijing 100191, China
| | - Li-Mei Liu
- Department of Physiology and Pathophysiology, Peking University Health Science Center, 38 Xue Yuan Road, Beijing 100191, China
| | - Yu-Ying Liu
- Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing 100191, China
| | - Juan Liu
- Department of Physiology and Pathophysiology, Peking University Health Science Center, 38 Xue Yuan Road, Beijing 100191, China
| | - Li Yan
- Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing 100191, China
| | - Chun-Shui Pan
- Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing 100191, China
| | - Ming-Xia Wang
- Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing 100191, China
| | - Chuan-She Wang
- Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing 100191, China; Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University, 38 Xue Yuan Road, Beijing 100191, China
| | - Jing-Yu Fan
- Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing 100191, China
| | - Yuan-Sheng Gao
- Department of Physiology and Pathophysiology, Peking University Health Science Center, 38 Xue Yuan Road, Beijing 100191, China.
| | - Jing-Yan Han
- Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing 100191, China; Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University, 38 Xue Yuan Road, Beijing 100191, China.
| |
Collapse
|
25
|
Icariside II improves cerebral microcirculatory disturbance and alleviates hippocampal injury in gerbils after ischemia–reperfusion. Brain Res 2014; 1573:63-73. [DOI: 10.1016/j.brainres.2014.05.023] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2014] [Revised: 05/01/2014] [Accepted: 05/13/2014] [Indexed: 11/18/2022]
|
26
|
Cardiotonic pill attenuates white matter and hippocampal damage via inhibiting microglial activation and downregulating ERK and p38 MAPK signaling in chronic cerebral hypoperfused rat. BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE 2013; 13:334. [PMID: 24274593 PMCID: PMC4222777 DOI: 10.1186/1472-6882-13-334] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/05/2013] [Accepted: 11/22/2013] [Indexed: 11/26/2022]
Abstract
Background The cardiotonic pill (CP) is a herbal medicine composed of Salvia miltiorrhiza (SM), Panax notoginseng (PN), and Dryobalanops aromatica Gaertner (DAG) that is widely used to treat cardiovascular diseases. The present experiment was conducted to examine the effects of CP on white matter and hippocampal damage induced by chronic cerebral hypoperfusion. Methods Chronic cerebral hypoperfusion was induced in male Wistar rats by permanent bilateral common carotid artery occlusion (BCCAo). Daily oral administration of CP (200 mg/kg) began 21 days after BCCAo and continued for 42 days. The levels of microglial activation and myelin basic protein (MBP) were measured in the white matter and hippocampus of rats with chronic BCCAo, and the expression levels of mitogen-activated protein kinases (MAPKs) and inflammatory markers such as cyclooxygenase-2, interleukin-1β, and interleukin-6 were examined. Results MBP expression was reduced in the white matter and hippocampal regions of rats that received BCCAo. In contrast, reduced levels of MBP were not observed in BCCAo rats given CP treatments. The administration of CP alleviated microglial activation, the alteration of ERK and p38 MAPK signaling, and inflammatory mediator expression in rats with chronic BCCAo. Conclusion These results suggest that CP may have protective effects against chronic BCCAo-induced white matter and hippocampal damage by inhibiting inflammatory processes including microglial activation and proinflammatory mediator expression, and downreguating the hyperphosphorylation of ERK and p38 MAPK signaling.
Collapse
|
27
|
Inhibition of NADPH Oxidase Mediates Protective Effect of Cardiotonic Pills against Rat Heart Ischemia/Reperfusion Injury. EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE 2013; 2013:728020. [PMID: 23840265 PMCID: PMC3690747 DOI: 10.1155/2013/728020] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/24/2013] [Revised: 05/14/2013] [Accepted: 05/22/2013] [Indexed: 02/07/2023]
Abstract
Cardiotonic pill (CP) is a compound Chinese medicine currently used in China for treatment of ischemic angina pectoris. Our previous results indicated that a single dosing of CP pretreatment at 0.8 g/kg attenuates ischemia/reperfusion- (I/R-) induced myocardial injury and cardiac microcirculatory disturbance. The present study aimed to investigate the effect of CP at low dosage in a multiple dosing manner and to uncover the mechanism of antioxidative activity of CP. Male Sprague-Dawley rats were subjected to left anterior descending artery occlusion for 30 min followed by 60 min reperfusion. CP was administrated daily by gavage for six days at 0.1, 0.4, and 0.8 g/kg/day before I/R. Results showed that multiple dosing of CP at three doses significantly reduced I/R-induced myocardial injury, microcirculatory disturbance, and oxidative stress. CP dramatically inhibited I/R-induced nicotinamide adenosine dinucleotide phosphate (NADPH) oxidase subunit gp91(phox) expression and p67(phox) and p47(phox) translocation from cytosol to cell membrane. Translocation of cytosolic subunits to membrane is required for the activation of NADPH oxidase. These data suggested that multiple dosing of CP at doses ranging from 0.1 to 0.8 g/kg/day reduced I/R-induced rat myocardial injury and microcirculatory disturbance, which was mediated by inhibition of NADPH oxidase activation.
Collapse
|